Health & Biotech
At Argent BioPharma, our mission is to revolutionize healthcare through pioneering innovation.
We go beyond traditional disease management by exploring the intricacies of the immune system and harnessing cutting-edge technologies in our research and development endeavors.
Through our commitment to advancing medical science, we aim to reshape the landscape of global healthcare by addressing unmet needs and offering hope to underserved populations worldwide.
Our vision encompasses becoming a leading biopharmaceutical company renowned for groundbreaking medical treatments. By embracing NanoPolyPharmacology, we strive to introduce impactful solutions that elevate standards within the life sciences industry. Our dedication extends to ensuring accessibility to innovative therapies for communities overlooked by conventional medical approaches, thereby bridging healthcare disparities on a global scale.
As we progress on this ambitious path, we invite you to follow our journey and be a part of a transformative shift in healthcare. At Argent BioPharma, we’re not just changing treatments; we’re changing lives.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Tech
These tech and pharma stocks are looking to M&A to drive growth in global markets
Health & Biotech
MGC Pharma extends working capital runway with $1.25 million raise
Health & Biotech
MGC’s ArtemiC validated by second US$1m order from AMC
Health & Biotech
ASX Health Stocks: AdAlta jumps 40pc after its fibrosis drug shows ‘potential efficacy’ in humans
Health & Biotech
Which ASX health companies are making strides in world’s largest healthcare market?
Health & Biotech
MGC Pharma welcomes Australia’s reclassification of psychedelic compounds
Health & Biotech
Weed Week: A ‘shroom boom’ could see psychedelics follow cannabis’ explosive footsteps
Health & Biotech
First UK patients receive MGC Pharma’s CannEpil product
Health & Biotech
MGC Pharma’s Malta facility is now GMP certified, opening door to markets such as the US
News
ASX Quarterly Wrap: Growing pipeline, milestones, and bullish guidance were the themes for these stocks
Health & Biotech
Could these Aussie psychedelics stocks carve a slice out of a ‘potential $63 billion’ global market?
Health & Biotech
MGC Pharma makes breakthrough after cannabis drug CannEpil made available to UK doctors
News
Closing Bell: When investors say ‘jump!’, the market says ‘how does 1.2% grab ya?’
Health & Biotech
Weed Week: Most Aussies still use illicit cannabis, but more are now turning to prescriptions
Health & Biotech
MGC Pharma granted approval in Slovenia to manufacture and conduct research into the burgeoning space of psychedelics
Experts
MoneyTalks: Two biotechs and a fitness stock that are set to blast off, according to brokers
News